DAE HWA Pharmaceutical Co. Ltd (067080) — Cash Flow-to-Debt Ratio
DAE HWA Pharmaceutical Co. Ltd (067080) has a Cash Flow-to-Debt Ratio of 0.00x as of March 2026, meaning its operating cash flow of ₩314.63 Million could theoretically repay 0% of its total liabilities (₩137.27 Billion) in one year. See DAE HWA Pharmaceutical Co. Ltd leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
DAE HWA Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for DAE HWA Pharmaceutical Co. Ltd across 15 annual periods. For the full cash flow conversion analysis, see 067080 cash flow conversion.
Annual Cash Flow-to-Debt Ratio for DAE HWA Pharmaceutical Co. Ltd (2011–2025)
Year-by-year debt coverage analysis for DAE HWA Pharmaceutical Co. Ltd. Check 067080 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.04x | ₩5.43 Billion | ₩131.72 Billion | ▼ -9.9% |
| 2024 | 0.05x | ₩6.13 Billion | ₩133.89 Billion | ▲ +1231.3% |
| 2023 | 0.00x | ₩-590.27 Million | ₩145.93 Billion | ▼ -106.1% |
| 2022 | 0.07x | ₩8.05 Billion | ₩121.06 Billion | ▼ -37.8% |
| 2021 | 0.11x | ₩10.45 Billion | ₩97.70 Billion | ▲ +243.1% |
| 2020 | 0.03x | ₩2.90 Billion | ₩93.07 Billion | ▲ +6686.3% |
| 2019 | 0.00x | ₩-41.07 Million | ₩86.80 Billion | ▼ -100.4% |
| 2018 | 0.12x | ₩10.49 Billion | ₩85.17 Billion | ▼ -0.2% |
| 2017 | 0.12x | ₩10.94 Billion | ₩88.72 Billion | ▲ +23.0% |
| 2016 | 0.10x | ₩8.79 Billion | ₩87.65 Billion | ▲ +162.2% |
| 2015 | 0.04x | ₩2.43 Billion | ₩63.55 Billion | ▼ -59.4% |
| 2014 | 0.09x | ₩6.18 Billion | ₩65.57 Billion | ▼ -58.4% |
| 2013 | 0.23x | ₩13.57 Billion | ₩59.84 Billion | ▲ +170.4% |
| 2012 | 0.08x | ₩5.77 Billion | ₩68.80 Billion | ▲ +92.2% |
| 2011 | 0.04x | ₩3.43 Billion | ₩78.60 Billion | — |